SeaChange Pharmaceuticals has introduced its similarity ensemble approach (SEA) software called SEAware for predictive matching of drugs with disease and toxicity targets.
SEAware provides analysis and visualization tools for prediction of drug and other small molecule activity and toxicity against biological targets.
SeaChange founder and COO Michael Keiser said SEAware has 10x the calculation speed and is a new, intuitive interface - 'google for drug targets.'
"Our pharma, academic, and government partners have found SEA most valuable in-house, where it's fast, easy, and secure," Keiser added.
SeaChange chief scientific officer Nicholas Hodge said that preclinical in vitro and in vivo testing of drug candidates against the increasing number of biological targets remains cost-prohibitive.
"One of the best uses of SEAware is as a predictive 'filter' to reduce the testing of molecules for activity or toxicity to a manageable number of targets," Hodge added.
"As clients become familiar with the method, and build curated reference libraries, the predictive accuracy - already high - will continue to improve."
SEAware enables exploration of new therapeutic uses for known drugs; mechanism of drug action; causes of side effects and adverse drug reactions as well as multi-target activity and polypharmacology.
